Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report first quarter 2026 financial results on April 28, 2026 with a conference call and live webcast at 8:30 a.m. ET.
Rhea-AI Summary
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report first quarter 2026 financial results on April 28, 2026 with a conference call and live webcast at 8:30 a.m. ET.
Telephone registration is required; webcast and a replay (available ~48 hours after the event) will be accessible via the company website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – KNSA
In the Apr 24 session, KNSA declined 0.60%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings call date
- April 28, 2026
- First quarter 2026 results conference call
- Call time
- 8:30 a.m. Eastern Time
- Start time for Q1 2026 conference call
- Replay timing
- 48 hours
- Replay available within ~48 hours after event
Previous Earnings date Reports
-
Announced date and webcast details for Q4 and full-year 2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.